Checkmate Pharmaceuticals P/E Ratio

Checkmate Pharmaceuticals (CMPI) currently reports a P/E ratio of -3.7. That is below the Healthcare sector average of 25.9. Use the charts on this page to explore Checkmate Pharmaceuticals's P/E ratio history and peer comparisons.

Checkmate Pharmaceuticals's P/E ratio of -3.7 is lower than the Healthcare sector average of 25.9. That is roughly 114.3% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

The P/E ratio is a valuation multiple that relates Checkmate Pharmaceuticals's market price to a fundamental measure such as earnings, sales, or book value. At -3.7, CMPI can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.

Start with the current P/E ratio of -3.7, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 25.9. From there, open related valuation or income-statement pages for Checkmate Pharmaceuticals, and consider following CMPI for alerts when major investors trade the stock.

Checkmate Pharmaceuticals is classified in the Healthcare sector. On P/E ratio, it currently shows -3.7 versus a sector average near 25.9. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CMPI with unrelated industries.